Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 11:27 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 79,266 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 2 Clear all
Completed Phase 1Phase 2 Interventional Results available

Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain

NCT01553916
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Lithium Carbonate, Prophylactic cranial irradiation
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Nov 2, 2026, 11:27 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Medical Illustration Design Characteristic Evaluation

NCT06435806
View directory record Official record
Conditions
Healthy
Interventions
Medical Illustration design
Other
Lead sponsor
Northeastern University
Other
Eligibility
18 Years and older
Enrollment
8,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Nov 2, 2026, 11:27 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers

NCT01408316
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PX-866
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Nov 2, 2026, 11:27 PM EST
Recruiting Not applicable Interventional

Effect of Giving Reduced Fluid in Children After Trauma

NCT04201704
View directory record Official record
Conditions
Critical Illness, Pediatrics, General Surgery, Fluid Therapy, Wounds and Injuries
Interventions
Balanced crystalloid solution volume administration, Packed Erythrocytes Units, Blood Product Unit volume, Plasma volume, Platelets volume
Other
Lead sponsor
Columbia University
Other
Eligibility
6 Months to 15 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Buffalo, New York • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Nov 2, 2026, 11:27 PM EST
Not yet recruiting Phase 3 Interventional

A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

NCT07890584
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism
Interventions
PLS240, Standard of Care
Drug · Combination Product
Lead sponsor
Pathalys Pharma
Industry
Eligibility
1 Month to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 2, 2026, 11:27 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

NCT03912233
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121, TEZ, VX-561, TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Los Angeles, California • Oakland, California • Lexington, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Nov 2, 2026, 11:27 PM EST
Completed Phase 1 Interventional

Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women

NCT00862433
View directory record Official record
Conditions
Diabetes, Fatty Liver, Obesity, Healthy Volunteers
Interventions
Alpha tocopherol, Vitamin E, Vitamin C
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 2, 2026, 11:27 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants

NCT05304533
View directory record Official record
Conditions
Healthy Participants
Interventions
MYK-224, Itraconazole, Verapamil
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Nov 2, 2026, 11:27 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials

NCT01376726
View directory record Official record
Conditions
HIV Infections
Interventions
Sub C gp140 Vaccine, MF59C.1 Adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
Birmingham, Alabama • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Nov 2, 2026, 11:27 PM EST
Terminated Phase 2 Interventional Results available

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

NCT04538378
View directory record Official record
Conditions
EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine
Interventions
Olaparib, Durvalumab, EKG, Tumor biopsy, CT chest, abdomen and pelvis, MRI chest, abdomen and pelvis
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 2, 2026, 11:27 PM EST
Completed Phase 4 Interventional Results available

Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes

NCT02964585
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Nov 2, 2026, 11:27 PM EST
Terminated Phase 3 Interventional

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

NCT02562443
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts, RAEB
Interventions
rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC)
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years to 81 Years
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Fleming Island, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Nov 2, 2026, 11:27 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Comparative Effects of Two Anesthetic Techniques on Auditory Brain Response in Children

NCT02830815
View directory record Official record
Conditions
Auditory Brainstem Response
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 18 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Nov 2, 2026, 11:27 PM EST
Completed Phase 1 Interventional

Chlorpromazine and Standard of Care in Glioblastoma

NCT05190315
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Chlorpromazine, Temozolomide, Radiation Therapy
Drug · Radiation
Lead sponsor
Mohammed Milhem
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Nov 2, 2026, 11:27 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Use Behavior, Nicotine Uptake, and Subjective Effects Comparison of Tobacco and Menthol e-Liquids by ENDS Consumers

NCT05134415
View directory record Official record
Conditions
Electronic Cigarette Use
Interventions
RELX ENDS Tobacco Flavor 1, RELX ENDS Tobacco Flavor 2, RELX ENDS Menthol Flavor 1, RELX ENDS Menthol Flavor 2
Other
Lead sponsor
Cheerain HK Limited
Industry
Eligibility
22 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Nov 2, 2026, 11:27 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

NCT04800315
View directory record Official record
Conditions
Dermatitis, Atopic, Eczema
Interventions
CC-93538, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
62
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Fountain Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Nov 2, 2026, 11:27 PM EST
Completed Phase 3 Interventional Results available

Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema

NCT00490815
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Nov 2, 2026, 11:27 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Radiofrequency and Ultrasound for Improvement of Skin Laxity and Wrinkles: Efficacy and Safety Evaluation

NCT05929625
View directory record Official record
Conditions
Skin Laxity
Interventions
BTL-585-2 RF+US, BTL-585-2 RF
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
21 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Birmingham, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Nov 2, 2026, 11:27 PM EST
Recruiting Phase 1 Interventional

A Study of LY3971297 in Participants With Heart Failure

NCT07547540
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
Interventions
LY3971297, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Detroit, Michigan • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 2, 2026, 11:27 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Vapocoolant Spray Used Prior to Intravenous (IV) Insertions

NCT03054740
View directory record Official record
Conditions
Pain
Interventions
Gebauer Ethyl Chloride, Nature's Tears
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Nov 2, 2026, 11:27 PM EST
Completed Phase 2 Interventional Results available

Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

NCT00857389
View directory record Official record
Conditions
Stem Cell Transplantation, Leukemia, Lymphoma
Interventions
Thiotepa, Clofarabine, Busulfan, Allogeneic Stem Cell Transplantation, Thymoglobulin (ATG), G-CSF (Filgrastim), Tacrolimus, Methotrexate, Cyclophosphamide, Mesna
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Nov 2, 2026, 11:27 PM EST
Terminated Not applicable Interventional

MiniTightRope Suspensionplasty Compared With LRTI for the Treatment of Basilar Thumb Arthritis

NCT02591368
View directory record Official record
Conditions
Arthritis, Joint Diseases
Interventions
Ligament reconstruction tendon interposition, Suspensionplasty with one-suture construct, Suspensionplasty with two-suture construct
Procedure
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Nov 2, 2026, 11:27 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

NCT03254784
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions
BMS-986165 Capsule, BMS-986165 Tablet
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Nov 2, 2026, 11:27 PM EST
Completed Phase 2 Interventional Results available

Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

NCT02867384
View directory record Official record
Conditions
Graft vs. Host Disease
Interventions
Obinutuzumab, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Nov 2, 2026, 11:27 PM EST